# Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons

> **NCT02403648** · PHASE1 · COMPLETED · sponsor: **Biodel** · enrollment: 15 (actual)

## Conditions studied

- Hypoglycemia

## Interventions

- **DRUG:** BIOD-961
- **DRUG:** Lilly Glucagon
- **DRUG:** Novo Glucagon

## Key facts

- **NCT ID:** NCT02403648
- **Lead sponsor:** Biodel
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2015-03
- **Final completion:** —
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2016-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02403648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02403648, "Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02403648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*